Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Novaccess Global Inc XSNX

Healthcare Biotechnology
NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.


OTCPK:XSNX - Post by User

Novaccess Global Inc > I strongly believe that this stock has potential
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by Peanutbudderon Jan 10, 2018 4:45pm
70 Views
Post# 27327808

RE:RE:RE:RE:RE:I strongly believe that this stock has potential

RE:RE:RE:RE:RE:I strongly believe that this stock has potential
VISION. Cali grows the most in US. Everywhere indoor would benefit from this.. if Sun were to establish a dominate energy sector in Cali they could show results to future clients in other states. Also they said themselves how they would fit into the Cannabis industry.. Probably trying to dig their feet in. MJ Will be bigger then alcohol.. if Sunx is putting systems on grow op after grow up as MJ expands so will sun.. more grow ops mor3 solar.. makes sense... world will run out of weed. More grow is needed. With that comes energy... you can set up green houses on inexpensice land and out in th3 middle of no wher3 and hook up solar. Lower property costs lower energy costs.. Would be a snowball affect. One company signs on and it would show in their financials what a increase in savings it was..
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities